Concord Drugs Ltd.

35.70 -0.20 ▼-0.6%

28 March 2024, 04:01:00 PM
Volume: 12,183

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.concorddrugs.in
Market Cap 35.17 Cr.
Enterprise Value(EV) 52.06 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 0.98 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 36.07 Trailing Twelve Months Ending 2023-12
Industry PE 41.54 Trailing Twelve Months Ending 2023-12
Book Value / Share 35.16 Trailing Twelve Months Ending 2023-12
Price to Book Value 1.00 Calculated using Price: 35.17
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 1.00 Cr. 10,000,000 Shares
FaceValue 10
About Concord Drugs Ltd.
Concord Drugs is engaged in developing new products Viz MUPS (Multiple Unit Pellet System), Sustained Release, Modified Release pellets with Innovative Drug Delivery Technologies by utilizing best and latest processing machinery.

Concord Drugs Ltd. Delivery

Delivered Qty
Traded Qty

Concord Drugs Ltd. Performance

1 Day
-0.56%
1 Week
+1.28%
1 Month
-9.73%
3 Month
-17.42%
6 Month
+8.02%
1 Year
+32.27%
2 Year
+19.40%
5 Year
+68.00%
10 Year

Concord Drugs Ltd. Fundamental Ratios

2 years 2022-03 2023-03
Return on Equity (%) 5.62 3.31
Return on Capital Employed (%) 8.77 6.32
Return on Assets (%) 2.82 1.72

Concord Drugs Ltd. Balance Sheet

Particulars 3 years 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 28 32 33
Non Curr. Liab. 4 5 5
Curr. Liab. 24 22 21
Minority Int.
Equity & Liab. 56 58 59
Non Curr. Assets 15 15 14
Curr. Assets 42 43 45
Misc. Exp. not W/O
Total Assets 56 58 59

Concord Drugs Ltd. Profit and Loss

Particulars 3 years 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 59 52 42
Other Income 0 0
Total Income 59 52 42
Total Expenditure -53 -48 -37
PBIDT 6 5 5
Interest -2 -2 -2
Depreciation -2 -2 -1
Taxation -1 0 0
Exceptional Items
PAT 2 1 1
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 2 1 1
Adjusted EPS 2 1 1

Concord Drugs Ltd. Cash Flow

Particulars 2 years 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 1 2
Cash Fr. Inv. -2 -2
Cash Fr. Finan. 2 1
Net Change 0 0
Cash & Cash Eqvt 0 0

Concord Drugs Ltd. Shareholding Pattern

9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 49.00 49.00 49.00 49.00 49.00 52.13 52.13 52.13 55.41
Public 51.00 51.00 51.00 51.00 51.00 47.87 47.87 47.87 44.59
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Concord Drugs Ltd. Announcements

Tue, 19 Mar 2024
Board Meeting Outcome for Appointment Of Company Secretary Cum Compliance Officer
Appointment of Ms. Namratha Nagla (ACS-68979) as Company Secretary Cum Compliance Officer
Tue, 19 Mar 2024
Appointment of Company Secretary and Compliance Officer
Appointment of Ms. Namratha Nagla as Company Secretary Cum Compliance Officer
Tue, 13 Feb 2024
Un-Audited Financial Results (Standalone And Consolidated) For The Quarter Ended 31St December 2023.
Un audited results (standalone and consolidated for the quarter ended 31.12.2023

Concord Drugs Ltd. Technical Scans

Thu, 28 Mar 2024
Close Below Last Month Low Close Below Last Month Low
High Decrease in 1 Month High Decrease in 1 Month
High Decrease in 3 Months High Decrease in 3 Months
High Increase in 1 Year High Increase in 1 Year
Doji and Near Doji Doji and Near Doji

Concord Drugs Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 388,812.23 1,620.50 +0.8%
Cipla Ltd. 120,673.12 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. 102,679.14 6,171.85 +2.0%
Zydus Lifesciences Ltd. 101,151.67 1,007.35 +0.8%
Mankind Pharma Ltd. 92,029.19 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. 91,330.58 6,347.35 +1.9%
Divi's Laboratories Ltd. 91,234.91 3,452.55 +2.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 43.66 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-12 32.54 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 19.64 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 34.01 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-12 53.29 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 115.71 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-12 65.97 3,452.55 +2.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 6.23 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-12 4.66 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.82 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.37 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-12 10.36 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 13.52 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-12 7.00 3,452.55 +2.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 0.02 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,452.55 +2.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 12.85 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,452.55 +2.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 12.85 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,452.55 +2.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,452.55 +2.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,452.55 +2.6%

Concord Drugs Ltd. FAQ's

What is Concord Drugs share price?

Can I buy Concord Drugs shares now?

What is the Market Cap of Concord Drugs?

What are the key metrics to analyse Concord Drugs?

What is the 52 Week High and Low of Concord Drugs?

What is the trend of Concord Drugs share price?